Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.

Autor: De Jaeghere EA; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium. Electronic address: emiel.dejaeghere@ugent.be., Hamerlinck H; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium. Electronic address: hannelore.hamerlinck@uzgent.be., Tuyaerts S; Gynaecologic Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Leuven Cancer Institute, Leuven, Belgium; Department of Medical Oncology, University Hospital Brussels, Brussels, Belgium; Laboratory for Medical and Molecular Oncology (LMMO), VUB, Brussels, Belgium. Electronic address: sandra.tuyaerts@uzbrussel.be., Lippens L; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium. Electronic address: lien.lippens@ugent.be., Van Nuffel AMT; Anticancer Fund (ACF), Strombeek-Bever, Belgium., Baiden-Amissah R; Gynaecologic Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Leuven Cancer Institute, Leuven, Belgium. Electronic address: reginaesimensimah.baidenamissah@kuleuven.be., Vuylsteke P; Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth), Namur, Belgium. Electronic address: peter.vuylsteke@uclouvain.be., Henry S; Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth), Namur, Belgium. Electronic address: stephanie.henry@uclouvain.be., Trinh XB; Department of Gynecologic Oncology and Senology, University Hospital Antwerp, Edegem, Belgium; Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp, Edegem, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Edegem, Belgium. Electronic address: xuanbich.trinh@uza.be., van Dam PA; Department of Gynecologic Oncology and Senology, University Hospital Antwerp, Edegem, Belgium; Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp, Edegem, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Edegem, Belgium. Electronic address: peter.vandam@uza.be., Aspeslagh S; Department of Medical Oncology, University Hospital Brussels, Brussels, Belgium. Electronic address: sandrine.aspeslagh@uzbrussel.be., De Caluwé A; Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium; Department of Radiation Oncology, General Hospital Sint-Maarten, Mechelen, Belgium. Electronic address: alex.decaluwe@bordet.be., Naert E; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Electronic address: eline.naert@ugent.be., Lambrechts D; VIB-KU Leuven Center for Cancer Biology, Belgium. Electronic address: diether.lambrechts@kuleuven.be., Hendrix A; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium. Electronic address: an.hendrix@ugent.be., De Wever O; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium. Electronic address: olivier.dewever@ugent.be., Van de Vijver KK; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Pathology, Ghent University Hospital, Ghent, Belgium; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center, Amsterdam, the Netherlands. Electronic address: koen.vandevijver@uzgent.be., Amant F; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center, Amsterdam, the Netherlands; Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium. Electronic address: f.amant@nki.nl., Vandecasteele K; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. Electronic address: katrien.vandecasteele@uzgent.be., Verhasselt B; Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium. Electronic address: bruno.verhasselt@uzgent.be., Denys HG; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Electronic address: hannelore.denys@ugent.be.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Dec; Vol. 191, pp. 275-286. Date of Electronic Publication: 2024 Nov 07.

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.

Autor: Vergote I; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium., Van Nieuwenhuysen E; Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Leuven Cancer Institute, Leuven, Belgium., O'Cearbhaill RE; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY., Westermann A; Dutch Gynaecological Oncology Group, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Lorusso D; Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Catholic University of Sacred Heart, Rome, Italy., Ghamande S; Department of Obstetrics and Gynecology, Augusta University, Augusta, GA., Collins DC; Department of Medical Oncology, Cancer Trials Ireland, Cork University Hospital, Cork, Ireland., Banerjee S; Royal Marsden National Health Service Foundation Trust, Institute of Cancer Research, London, United Kingdom., Mathews CA; Program in Women's Oncology, Women & Infants Hospital, Legorreta Cancer Center at Alpert Medical School of Brown University, Providence, RI., Gennigens C; BGOG, Centre Hospitalier Universitaire de Liège, Liège, Belgium., Cibula D; Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Tewari KS; University of California, Irvine, CA., Madsen K; Centre for Cancer and Organ Diseases, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark., Köse F; Baskent University, Ankara, Turkey., Jackson AL; Department of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati, OH., Boere IA; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Scambia G; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Randall LM; School of Medicine, Virginia Commonwealth University, Richmond, VA., Sadozye A; Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, United Kingdom., Baurain JF; Cliniques Universitaires Saint-Luc and Université Catholique de Louvain and BGOG, Brussels, Belgium., Gort E; University Medical Center Utrecht, Utrecht, the Netherlands., Zikán M; First Faculty of Medicine, Bulovka University Hospital, Charles University, Prague, Czech Republic., Denys HG; BGOG, Ghent University Hospital, Ghent, Belgium., Ottevanger N; Radboudumc, Nijmegen, the Netherlands., Forget F; BGOG, Centre Hospitalier de l'Ardenne-Site de Libramont, Libramont-Chevigny, Belgium., Mondrup Andreassen C; Genmab A/S, Copenhagen, Denmark., Eaton L; Genmab US, Princeton, NJ., Chisamore MJ; Merck & Co, Inc, Rahway, NJ., Viana Nicacio L; Seagen, Bothell, WA., Soumaoro I; Genmab US, Princeton, NJ., Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 20; Vol. 41 (36), pp. 5536-5549. Date of Electronic Publication: 2023 Aug 31.

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Autor: De Jaeghere EA; Department of Medical Oncology (Route 535), Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium., Tuyaerts S; Gynaecologic Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.; Leuven Cancer Institute, Leuven, Belgium.; Department of Medical Oncology, University Hospital Brussels, Brussels, Belgium.; Laboratory for Medical and Molecular Oncology (LMMO), VUB, Brussels, Belgium., Van Nuffel AMT; Anticancer Fund (ACF), Strombeek-Bever, Belgium., Belmans A; Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven, Belgium., Bogaerts K; Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven, Belgium., Baiden-Amissah R; Gynaecologic Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.; Leuven Cancer Institute, Leuven, Belgium., Lippens L; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium., Vuylsteke P; Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth), Namur, Belgium., Henry S; Department of Hemato-Oncology, Centre Hospitalier Universitaire Université Catholique de Louvain Namur (Sainte-Elisabeth), Namur, Belgium., Trinh XB; Department of Gynecologic Oncology and Senology, University Hospital Antwerp, Edegem, Belgium.; Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Edegem, Belgium., van Dam PA; Department of Gynecologic Oncology and Senology, University Hospital Antwerp, Edegem, Belgium.; Multidisciplinary Oncologic Centre Antwerp (MOCA), University Hospital Antwerp, Edegem, Belgium.; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Edegem, Belgium., Aspeslagh S; Department of Medical Oncology, University Hospital Brussels, Brussels, Belgium., De Caluwé A; Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium.; Department of Radiation Oncology, General Hospital Sint-Maarten, Mechlin, Belgium., Naert E; Department of Medical Oncology (Route 535), Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Lambrechts D; VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium., Hendrix A; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium., De Wever O; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium., Van de Vijver KK; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Pathology, Ghent University Hospital, Ghent, Belgium.; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center, Amsterdam, The Netherlands., Amant F; Gynaecologic Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.; Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam Medical Center, Amsterdam, The Netherlands.; Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium., Vandecasteele K; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium., Denys HG; Department of Medical Oncology (Route 535), Ghent University Hospital, C. Heymanslaan 10, 9000, Ghent, Belgium. hannelore.denys@ugent.be.; Cancer Research Institute Ghent (CRIG), Ghent, Belgium. hannelore.denys@ugent.be.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Feb; Vol. 72 (2), pp. 475-491. Date of Electronic Publication: 2022 Aug 12.

Splenic ¹⁸ F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer.

Autor: De Jaeghere EA; Medical Oncology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; Laboratory of Experimental Cancer Research (LECR), Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium. Electronic address: emiel.dejaeghere@ugent.be., Laloo F; Radiology and Nuclear Medicine, Department of Diagnostic Sciences, Ghent University Hospital, Belgium., Lippens L; Medical Oncology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; Laboratory of Experimental Cancer Research (LECR), Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium., Van Bockstal M; Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., De Man K; Radiology and Nuclear Medicine, Department of Diagnostic Sciences, Ghent University Hospital, Belgium., Naert E; Medical Oncology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium., Van Dorpe J; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Pathology, Department of Diagnostic Sciences, Ghent University Hospital, Belgium., Van de Vijver K; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium; Pathology, Department of Diagnostic Sciences, Ghent University Hospital, Belgium., Tummers P; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium; Gynecology, Department of Human Structure and Repair, Ghent University Hospital, Belgium., Makar A; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium; Gynecology, Department of Human Structure and Repair, Ghent University Hospital, Belgium., De Visschere PJL; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium; Radiology and Nuclear Medicine, Department of Diagnostic Sciences, Ghent University Hospital, Belgium., De Wever O; Laboratory of Experimental Cancer Research (LECR), Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium., Amant F; Centers Gynecologic Oncology Amsterdam, Netherlands Cancer Institute and Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Oncology, KU Leuven, Leuven, Belgium., Denys HG; Medical Oncology, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium., Vandecasteele K; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; Gynecological Pelvic Oncology Network (GYPON), Ghent, Belgium; Radiation Oncology, Department of Human Structure and Repair, Ghent University Hospital, Belgium.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2020 Nov; Vol. 159 (2), pp. 335-343. Date of Electronic Publication: 2020 Aug 25.

Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.

Autor: De Jaeghere EA; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Gremonprez FB; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Tummers PG; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Willaert WC; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Ceelen WP; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Amant FC; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium., Denys HG; Emiel A. De Jaeghere, MD; Félix B. Gremonprez, MD, PhD; Philippe G. Tummers, MD, PhD; Wouter C. Willaert, MD, PhD; and Wim P. Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium; Frédéric C. Amant, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Hannelore G. Denys, MD, PhD, Ghent University Hospital, Ghent, Belgium.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Nov 20; Vol. 37 (33), pp. 3169-3170. Date of Electronic Publication: 2019 Sep 25.